These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 6098977)
21. Studies on osteoporosis I. Experimental models. Effect of age, sex, genetic background, diet, steroid and heparin treatment on calcium metabolism of mice. Ambrus JL; Robin JC; Kelly RS; Mannley N; Thomas CC; Ambrus JL Res Commun Chem Pathol Pharmacol; 1978 Oct; 22(1):3-14. PubMed ID: 725319 [TBL] [Abstract][Full Text] [Related]
22. HRT dosing regimens: continuous versus cyclic-pros and cons. Shoupe D Int J Fertil Womens Med; 2001; 46(1):7-15. PubMed ID: 11294619 [TBL] [Abstract][Full Text] [Related]
23. [Basic principles of hormone replacement therapy in the postmenopause]. Dören M Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374 [TBL] [Abstract][Full Text] [Related]
24. Calcium, estrogen, and progestin in the treatment of osteoporosis. Breslau NA Rheum Dis Clin North Am; 1994 Aug; 20(3):691-716. PubMed ID: 7984785 [TBL] [Abstract][Full Text] [Related]
25. [Postmenopausal estrogen therapy: pharmacological treatment or replacement of the lacking hormone?]. Lippert TH; Seeger H; Mueck AO Dtsch Med Wochenschr; 1999 Oct; 124(42):1245-8. PubMed ID: 10572534 [No Abstract] [Full Text] [Related]
26. [Application of new therapeutic approaches in the prevention of osteoporosis in women]. Bocci A; Campagnoli C; Ardizzoia M Minerva Endocrinol; 1989; 14(1):75-80. PubMed ID: 2733648 [TBL] [Abstract][Full Text] [Related]
27. Effect of estrogen (Premarin) replacement therapy on serum level of total estrogen and urinary excretion of calcium and hydroxyproline in postmenopausal Chinese women. Ouyang PC; Chow SN; Huang SC; Hsieh CY Proc Natl Sci Counc Repub China B; 1986 Jul; 10(3):162-6. PubMed ID: 3022320 [TBL] [Abstract][Full Text] [Related]
28. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women. Palacios S; Mejía Ríos A Drugs Today (Barc); 2015 Feb; 51(2):107-16. PubMed ID: 25756066 [TBL] [Abstract][Full Text] [Related]
29. [Estrogens and gestagens in the prevention of osteoporosis]. Lauritzen C Zentralbl Gynakol; 1991; 113(8):475-8. PubMed ID: 1651636 [No Abstract] [Full Text] [Related]
30. The risk of breast cancer after estrogen and estrogen-progestin replacement. Bergkvist L; Adami HO; Persson I; Hoover R; Schairer C N Engl J Med; 1989 Aug; 321(5):293-7. PubMed ID: 2546079 [TBL] [Abstract][Full Text] [Related]
31. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Vercellini P; Pietropaolo G; De Giorgi O; Pasin R; Chiodini A; Crosignani PG Fertil Steril; 2005 Nov; 84(5):1375-87. PubMed ID: 16275232 [TBL] [Abstract][Full Text] [Related]
32. Actions of progestins on the morphology and biochemistry of the endometrium of postmenopausal women receiving low-dose estrogen therapy. Whitehead MI; Townsend PT; Pryse-Davies J; Ryder T; Lane G; Siddle N; King RJ Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):791-5. PubMed ID: 6278933 [TBL] [Abstract][Full Text] [Related]
33. Studies on osteoporosis IV. Effect of benzo[b]thiophene-2- and dibenzothiophene-4-carboxylic acid on heparin accelerated osteoporosis. Robin JC; Sharma SD; Francis K; Rosenstein M; Moore R; Vida JA; Thomas CC; Ambrus JL J Med; 1980; 11(1):15-27. PubMed ID: 6931182 [TBL] [Abstract][Full Text] [Related]
34. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568 [TBL] [Abstract][Full Text] [Related]
36. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause. Tella SH; Gallagher JC Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499 [TBL] [Abstract][Full Text] [Related]
37. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694 [TBL] [Abstract][Full Text] [Related]
39. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Stefanick ML Am J Med; 2005 Dec; 118 Suppl 12B():64-73. PubMed ID: 16414329 [TBL] [Abstract][Full Text] [Related]
40. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]